Low-dose IL-2 for lupus patients with cytomegalovirus infection
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests whether a low dose of a drug called IL-2 can help control both lupus and a common virus called cytomegalovirus (CMV). It may reduce lupus symptoms while helping your body fight off the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus (meeting standard criteria).
- A blood test shows you have an active CMV infection (positive viral load).
- You are between 18 and 65 years old and weigh between 45 and 80 kg (about 99 to 176 pounds).
- You are currently taking a steroid medication at a dose less than 1.0 mg per kg per day.
- You do not have other active infections (like hepatitis B or C, HIV, or tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This study tests whether a low dose of a protein called IL-2 can safely help control the immune system in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to reduce disease activity and improve symptoms.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This trial tests a low dose of IL-2 to reduce inflammation and help control Crohn’s disease symptoms. It’s for people whose Crohn’s disease hasn’t responded to at least one standard treatment or who need steroids to stay under control.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.